Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valproic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valproic Acid SCHEMBL1330837 | 1.00 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2275 | 1.00 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL6910916 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL7579608 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2054191 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL69795 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1738242 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL21378840 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL139238 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2184648 | 0.97 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103416943-A | Method and apparatus for quickly cleaning and cleansing hair | LIN BINGSONG | 2013-12-04 | — | — | CN | claimed |
| US-12630629-B2 | Anti-IGSF1 antibody and use thereof | WELLMARKER BIO CO., LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| CN-113767115-B | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119546298-A | 5-Methoxy-N, N-dimethyltryptamine for the treatment of cognitive dysfunction | GH研究爱尔兰有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119278036-A | 5-MeO-DMT for the treatment of sleep disorders | GH研究爱尔兰有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119255799-A | 5-MEO-DTM for the treatment of bipolar disorders | GH研究爱尔兰有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119255798-A | 5-Methoxy-N, N-dimethyltryptamine for the treatment of social/emotional withdrawal or distraction | GH研究爱尔兰有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119156212-A | Treatment of post partum depression | GH研究爱尔兰有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2007084541-A2 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007038524-A2 | COCRYSTALLIZATION METHODS | SSCI, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-7148257-B2 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1682152-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS Response (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005044190-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS RESPONSE (US) | 2005-05-19 | — | — | WO | disclosed |
| US-4442124-A | Valproic acid ester with antiepileptic and anticonvulsant activity and pharmaceutical compositions therefrom | TEXCONTOR-ANSTALT (LI) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630629-B2 | Anti-IGSF1 antibody and use thereof | IGSF11, IGLV6-57, IKZF1 | CHRM1 3716/4885AKR1A1 4372/4885CHRM3 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.